Syndax Pharmaceuticals Inc
SNDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001395937
In the last 90 days, Syndax Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 242 institutions reported holding it in 13F filings for Q2 2026, worth $2.36B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $784.8K in total
- 1
- 13F holdersQ2 2026, −2 vs. previous quarter
- 242
- 13F valueReported value at the end of Q2 2026
- $2.36B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SNDX, Q2 2026
No superinvestor reported holding SNDX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Syndax Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 (view filing)4:54 PM ET | Jul 8 | 1 day | Metzger Michael AChief Executive Officer | SSale | −32.4K | $24.24 | −$784.8K | −6.3%484.8K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 11-12 | 1 day | Botwood Nicholas A.J.Head of R&D, CMO | SSale | −65.5K | $18.07 | −$1.18M | −51.8%60.9K after | 2 lots10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Goldan Keith A.Chief Financial Officer | SSale | −1.18K | $18.99 | −$22.4K | −0.8%139.3K after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Metzger Michael AChief Executive Officer | SSale | −6.85K | $18.99 | −$130.0K | −1.4%484.8K after | |
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | Metzger Michael AChief Executive Officer | SSale | −17.2K | $21.03 | −$360.9K | −3.4%491.7K after | |
| Feb 10, 2026 (view filing) | Feb 9 | 1 day | Goldan Keith A.Chief Financial Officer | SSale | −3.41K | $21.03 | −$71.7K | −2.4%140.4K after | |
| Feb 6, 2026 (view filing) | Feb 6 | Same day | Metzger Michael AChief Executive Officer | SSale | −7.41K | $20.62 | −$152.8K | −1.4%508.8K after | |
| Feb 6, 2026 (view filing) | Feb 6 | Same day | Goldan Keith A.Chief Financial Officer | SSale | −2.08K | $20.62 | −$42.9K | −1.4%143.8K after | |
| Sep 8, 2025 (view filing) | Sep 8 | Same day | Metzger Michael AChief Executive Officer | SSale | −157.3K | $16.41 | −$2.58M | −34.5%298.7K after | 10b5-1 |
| Aug 18, 2025 (view filing) | Aug 14-18 | 4 days | Podlesak DennisDirector | SSale | −57.6K | $15.19 | −$874.9K | −23.1%191.8K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Syndax Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,020,006 | $197.2M | 0.00% | +765,580+9.3% | Added |
| Kynam Capital Management, LP | 8,050,959 | $176.0M | 9.73% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 5,861,265 | $128.1M | 0.01% | +864,478+17.3% | Added |
| State Street Corp | 5,658,424 | $123.7M | 0.00% | +1,228,348+27.7% | Added |
| Bank of America Corp | 4,045,094 | $88.4M | 0.01% | −204,742−4.8% | Reduced |
| Vanguard Capital Management LLC | 3,927,892 | $85.9M | 0.00% | +105,313+2.8% | Added |
| Deerfield Management Company, L.P. (Series C) | 3,779,900 | $82.6M | 0.86% | 00.0% | Unchanged |
| Eversept Partners, LP | 2,798,210 | $61.2M | 3.33% | −87,412−3.0% | Reduced |
| Geode Capital Management, LLC | 2,584,136 | $56.5M | 0.00% | +427,078+19.8% | Added |
| Hood River Capital Management LLC | 2,564,279 | $56.1M | 0.41% | +209,994+8.9% | Added |